Multiple Myeloma
Conditions
Keywords
Asymptomatic
Brief summary
Purpose: The purpose of this study is to see if TBL 12, which is a blend of Sea Cucumber, Sea Sponge, Shark Fin, and Sea Urchin (animals that live in the Pacific Ocean) as well as Sargassum (a plant that lives in the Pacific Ocean), will have effects against asymptomatic multiple myeloma and to see what the side effects are. Eligibility: Several criteria must be met to be eligible for this study, including but not limited to the following: * a diagnosis of asymptomatic multiple myeloma * adequate cardiac, liver and kidney function * age 18 and older
Detailed description
Multiple myeloma is a cancer that evolves from a state known as Monoclonal Gammopathy of Undetermined Significance (MGUS), defined by parameters of M spike and bone marrow. After evolution to myeloma, patients may be asymptomatic, that is, without any endorgan disease of hypercalcemia, renal insufficiency, anemia or bone lesions. In asymptomatic myeloma (ASxM), there is no standard therapy. Thalidomide has been tried in patients with ASxM but with significant toxicity. The patients with ASxM are evaluable in terms of paraprotein measurements. TBL12 sea cucumber extract has been shown to have a number of antitumor properties preclinically, including antiangiogenesis and direct tumor cytotoxicity. TBL12 has been used by a number of patients as a food supplement without any toxicity detected. We thus propose to determine the clinical activity of this agent in patients with ASxM. Patients will be given TBL12 at the dose of 2 units of 20 mL each twice per day daily for one year and the effects on the paraprotein noted. Clinical effects seen will be correlated with any in vitro changes in angiogenesis in patient bone marrow samples. The results of this trial may form the basis for the use of this nontoxic agent in patients with the prodrome of or with other early cancers.
Interventions
DRUGTBL 12
TBL 12 will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression.
Sponsors
Unicorn Pacific Corporation
Jagannath, Sundar, M.D.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of multiple myeloma * Measurable disease * For non-secretors, measurable protein by Freelite or plasmacytoma * Asymptomatic disease
Exclusion criteria
* POEMS syndrome * Plasma cell leukemia * Receiving steroids greater than the equivalent of 10 mg prednisone * Infection not controlled by antibiotics * HIV infection * Known active hepatitis B or C
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to Progression | From date of treatment until the date of first documented progression | To determine the time to progression of asymptomatic multiple myeloma patients receiving TBL 12. The time to progression will be measured in units of a cycle (28 day cycles). Progression is defined using the International Uniform Response Criteria for Multiple Myeloma (Leukemia (2006)20:1467-1473). Which requires one or more of the following: \>25% increase in SPEP (must also be an absolute increase of at least 5 g/dL), \>25% increase in UPEP (must also be an absolute increase of at least 200 mg/24 hours), \>25% increase in bone marrow plasma cells (must also be an absolute increase of at least 10%), new lytic bone lesions or soft tissue plasmacytomas, or development of hypercalcemia (not attributable to any other cause). |
| Response Rate | from date of start of treatment until the date of best documented response up to date of progression | The response rate - percentage of participants with overall response. Overall response for any participants that has achieved at least a PR or better (PR, VGPR, CR, sCR) is defined using the International Uniform Response Criteria for Multiple Myeloma (Leukemia (2006)20:1467-1473) . Which requires the following: at least \>50% reduction in SPEP, at least \>90% reduction or \<200 mg in UPEP, at least \>50% reduction in the size of soft tissue plasmacytomas, no lytic bone lesions or similar definition that is accurate and appropriate. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Antitumor Effect | Antitumor effect | To study the possible mechanisms involved in the clinical antitumor effect with determination of inhibition of angiogenesis |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| TBL 12 TBL 12, sea cucumber, will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression | 20 |
| Total | 20 |
Baseline characteristics
| Characteristic | TBL 12 |
|---|---|
| Age, Continuous | 58 years |
| Bone Marrow Plasmacytosis | 38 percentage of participants |
| Region of Enrollment United States | 20 participants |
| Sex: Female, Male Female | 9 Participants |
| Sex: Female, Male Male | 11 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 1 / 20 |
| serious Total, serious adverse events | 1 / 20 |
Outcome results
Primary
Response Rate
The response rate - percentage of participants with overall response. Overall response for any participants that has achieved at least a PR or better (PR, VGPR, CR, sCR) is defined using the International Uniform Response Criteria for Multiple Myeloma (Leukemia (2006)20:1467-1473) . Which requires the following: at least \>50% reduction in SPEP, at least \>90% reduction or \<200 mg in UPEP, at least \>50% reduction in the size of soft tissue plasmacytomas, no lytic bone lesions or similar definition that is accurate and appropriate.
Time frame: from date of start of treatment until the date of best documented response up to date of progression
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| TBL 12 | Response Rate | 5 percentage of participants |
Primary
Time to Progression
To determine the time to progression of asymptomatic multiple myeloma patients receiving TBL 12. The time to progression will be measured in units of a cycle (28 day cycles). Progression is defined using the International Uniform Response Criteria for Multiple Myeloma (Leukemia (2006)20:1467-1473). Which requires one or more of the following: \>25% increase in SPEP (must also be an absolute increase of at least 5 g/dL), \>25% increase in UPEP (must also be an absolute increase of at least 200 mg/24 hours), \>25% increase in bone marrow plasma cells (must also be an absolute increase of at least 10%), new lytic bone lesions or soft tissue plasmacytomas, or development of hypercalcemia (not attributable to any other cause).
Time frame: From date of treatment until the date of first documented progression
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| TBL 12 | Time to Progression | 15 cycles |
Secondary
Antitumor Effect
To study the possible mechanisms involved in the clinical antitumor effect with determination of inhibition of angiogenesis
Time frame: Antitumor effect
Population: immunophenotyping was not performed in this study